Theodore E. Hebert

Array ( [id] => 16469554 [patent_doc_number] => 20200371091 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/768260 [patent_app_country] => US [patent_app_date] => 2018-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 120154 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -69 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16768260 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17858482 [patent_doc_number] => 11439620 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-13 [patent_title] => Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors [patent_app_type] => utility [patent_app_number] => 16/204297 [patent_app_country] => US [patent_app_date] => 2018-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 22 [patent_no_of_words] => 34751 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16204297 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16998359 [patent_doc_number] => 11077141 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-03 [patent_title] => Anti-tumor T cell immunity induced by high dose radiation [patent_app_type] => utility [patent_app_number] => 16/202769 [patent_app_country] => US [patent_app_date] => 2018-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 23 [patent_no_of_words] => 11196 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16202769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17695985 [patent_doc_number] => 11369687 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-28 [patent_title] => Receptor targeting constructs and uses thereof [patent_app_type] => utility [patent_app_number] => 16/197240 [patent_app_country] => US [patent_app_date] => 2018-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 50 [patent_no_of_words] => 17794 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16197240 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17539872 [patent_doc_number] => 11304976 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-19 [patent_title] => Combination immune therapy and cytokine control therapy for cancer treatment [patent_app_type] => utility [patent_app_number] => 16/194417 [patent_app_country] => US [patent_app_date] => 2018-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 66 [patent_no_of_words] => 91724 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16194417 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18886426 [patent_doc_number] => 11865182 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-09 [patent_title] => Product and process for employing GC7 (N1-guanyl-1,7-diaminoheptane) based antigen binding conjugates in cancer therapy [patent_app_type] => utility [patent_app_number] => 16/764859 [patent_app_country] => US [patent_app_date] => 2018-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 20 [patent_no_of_words] => 6087 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16764859 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16451005 [patent_doc_number] => 20200360431 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, CD19-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND COMBINATION THERAPIES [patent_app_type] => utility [patent_app_number] => 16/764459 [patent_app_country] => US [patent_app_date] => 2018-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67525 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16764459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18887966 [patent_doc_number] => 11866731 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-09 [patent_title] => Modified immune cells and uses thereof [patent_app_type] => utility [patent_app_number] => 15/733076 [patent_app_country] => US [patent_app_date] => 2018-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 47 [patent_no_of_words] => 35843 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 154 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15733076 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16498892 [patent_doc_number] => 10864259 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-15 [patent_title] => Methods and compositions for the treatment of melanoma [patent_app_type] => utility [patent_app_number] => 16/184086 [patent_app_country] => US [patent_app_date] => 2018-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 17024 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16184086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19274604 [patent_doc_number] => 12024715 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-02 [patent_title] => Compositions and methods for improved T cells [patent_app_type] => utility [patent_app_number] => 16/761599 [patent_app_country] => US [patent_app_date] => 2018-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 42941 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16761599 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18193660 [patent_doc_number] => 20230047179 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => ANTIBODIES AGAINST MFAP4 [patent_app_type] => utility [patent_app_number] => 16/760490 [patent_app_country] => US [patent_app_date] => 2018-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11410 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16760490 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18012145 [patent_doc_number] => 11504419 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-22 [patent_title] => Individualized vaccines for cancer [patent_app_type] => utility [patent_app_number] => 16/172063 [patent_app_country] => US [patent_app_date] => 2018-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 41 [patent_no_of_words] => 45428 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16172063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16977664 [patent_doc_number] => 20210221901 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => Methods of Reducing Side Effects of Anti-CD30 Antibody Drug Conjugate Therapy [patent_app_type] => utility [patent_app_number] => 16/755403 [patent_app_country] => US [patent_app_date] => 2018-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15304 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -96 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16755403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13867669 [patent_doc_number] => 20190030175 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER [patent_app_type] => utility [patent_app_number] => 16/157547 [patent_app_country] => US [patent_app_date] => 2018-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58364 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16157547 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18575528 [patent_doc_number] => 11732042 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-22 [patent_title] => Compositions and methods for using the CD2-based signaling pathways to block HIV infection [patent_app_type] => utility [patent_app_number] => 16/755176 [patent_app_country] => US [patent_app_date] => 2018-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 2596 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16755176 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16640900 [patent_doc_number] => 10918721 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-16 [patent_title] => Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity [patent_app_type] => utility [patent_app_number] => 16/155423 [patent_app_country] => US [patent_app_date] => 2018-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 45 [patent_no_of_words] => 60959 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16155423 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13986545 [patent_doc_number] => 20190062430 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => FLAG TAGGED CD19-CAR-T CELLS [patent_app_type] => utility [patent_app_number] => 16/148806 [patent_app_country] => US [patent_app_date] => 2018-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6218 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16148806 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16876893 [patent_doc_number] => 11027013 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-08 [patent_title] => Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor [patent_app_type] => utility [patent_app_number] => 16/148257 [patent_app_country] => US [patent_app_date] => 2018-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 11114 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16148257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16040993 [patent_doc_number] => 10682347 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-16 [patent_title] => Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity [patent_app_type] => utility [patent_app_number] => 16/145755 [patent_app_country] => US [patent_app_date] => 2018-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 14 [patent_no_of_words] => 55104 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16145755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14099059 [patent_doc_number] => 20190091205 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => Methods and compositions for inhibiting mutant EGFR signaling [patent_app_type] => utility [patent_app_number] => 16/146611 [patent_app_country] => US [patent_app_date] => 2018-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13858 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16146611 [rel_patent_id] =>[rel_patent_doc_number] =>)